Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11507MR)

This product GTTS-WQ11507MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11507MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6304MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ7770MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ11262MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ12907MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ12805MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ11763MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ2076MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ8135MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW